Oncology Case Study

Strategic appointments help a company commercialise and grow

Setting the Scene

In the extremely dynamic Oncology market, where big pharma has a stronghold, many successes are nevertheless driven by the acquisitions of small biotech assets. This company has several prostate cancer approved drugs on the market including the first marketed injectable targeted radio pharmaceutical for cancer. In 2013 the company was acquired for $2.9 billion.

A Close Partnership from the Start

We were first introduced to this client in 2005 when a Board member learned of our outstanding reputation for hiring top flight senior management in the life sciences space and presented Coulter Partners to them. At this time the company had €23 million in funding from their investors. A strong relationship was subsequently built on the successful delivery of key hires including 3 CMOs, a highly impactful, transformational CEO, a CBO, a CSO, a SVP Protein Therapeutics and a BD Director.

On the back of the close partnership that the team built with this client, Arnaldo and Zdenka cultivated many new relationships with Nordic companies. We were then fortunate enough to recruit Eskil and Nicolaj for our own team, with their extensive track record in the Nordics, and so boost this growth market for Coulter Partners

The Impact of Strong Leadership Hires

With such stellar leadership, the client was able to gain global recognition and both EMA and FDA approval for their leading asset. Coulter Partners has been an influential partner to the company from its earliest clinical stage, when it had just completed its IPO on OsloSTEX. Now one of the most valuable capitalised biotechs in Europe, they are providing exceptional returns to their investors.